USFDA says possible carcinogens found in Merck's Sitagliptin drugs Januvia, Janumet

The U.S. Food and Drug Administration said on Tuesday certain samples of sitagliptin, a compound in Merck's diabetes drugs Januvia and Janumet, were contaminated with a possible carcinogen.

The agency said it would temporarily allow Merck to distribute drugs with sitagliptin containing a higher than normally acceptable amount of the impurity Nitroso-STG-19, also known as NTTP, in order to avoid a shortage.

For more details, check out the full story on the link below:

Possible Carcinogens Found in Merck's Sitagliptin Drugs Januvia, Janumet: USFDA